📊 Evidence-Based Reference

gore viabahn endoprosthesis and gore viabahn endoprosthesis with heparin bioactive surface

W.L. Gore & Associates

Summary: The GORE VIABAHN Endoprosthesis is a stent graft used primarily for peripheral artery disease. Key evidence highlights its effectiveness in maintaining vessel patency and managing in-stent restenosis.

FDA Clearance Information

Pathway PMA
Decision Date May 13, 2019
Product Code NIP
Device Class Class 3
Evidence 33 studies

The GORE VIABAHN Endoprosthesis was cleared by the FDA via the PMA pathway on May 13, 2019. It is manufactured by W.L. Gore & Associates and classified as a Class 3 device.

What It Is

The GORE VIABAHN Endoprosthesis is a flexible, self-expanding stent graft designed to treat peripheral artery disease by maintaining vessel patency. It is used in endovascular procedures to manage complex lesions, particularly in the superficial femoral artery.

Clinical Applications

Commonly used in the treatment of peripheral artery disease, the GORE VIABAHN Endoprosthesis is applied in scenarios such as in-stent restenosis and complex femoropopliteal lesions. It is particularly useful in cases where previous interventions have failed.

Evidence Summary

The literature includes 15 studies, comprising RCTs, prospective, and retrospective analyses, conducted between 2016 and 2024. These studies evaluate the device's effectiveness and safety in various clinical settings.

Reported Outcomes

Published studies report that the GORE VIABAHN Endoprosthesis achieves primary patency rates of 62.4% and secondary patency rates of 82.3% over five years. It also shows a significant mean improvement in Rutherford classification by 2.3 points, indicating effective symptom relief.

Safety Profile

Reported complications include a cumulative device-related serious adverse event rate of 19.9%, with 9.3% occurring after the first year. Notably, there were no reported stent fractures, indicating a favorable safety profile.

Evidence Limitations

While the studies provide valuable insights, limitations include a lack of long-term data beyond five years and variability in study designs. Further research is needed to explore outcomes in diverse patient populations and long-term durability.

Linked Studies (20)

PubMed • 2025

Popliteal Arteriovenous Fistula Diagnosed Eight Years after Total Knee Arthroplasty. Endovascular Treatment with Viabahn® Endoprosthesis and Five-Year Follow-Up.

Reports (MDPI)

Other View Source →
PubMed • 2024

Mid-Term Outcomes of the Viabahn Balloon-Expandable Endoprosthesis as Bridging Stent Graft for Fenestrated and Branched Endovascular Aortic Repair.

Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists

RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2024

Laser Atherectomy and Restenting of the Superficial Femoral Artery Using GORE VIABAHN Endoprosthesis Following Failure of Both Bare-Metal Stenting and Surgical Revascularization.

Case reports in vascular medicine

View Source →
PubMed • 2024

Five-year outcomes of the GORE VIABAHN Endoprosthesis for the treatment of complex femoropopliteal lesions from a Japanese postmarket surveillance study.

Vascular medicine (London, England)

Prospective View Source →
PubMed • 2024

Three-Year Results of the GORE VIABAHN Endoprosthesis in the Superficial Femoral Artery for In-Stent Restenosis.

Journal of the Society for Cardiovascular Angiography & Interventions

RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2024

Erratum: Three-Year Results of the GORE VIABAHN Endoprosthesis in the Superficial Femoral Artery for In-Stent Restenosis.

Journal of the Society for Cardiovascular Angiography & Interventions

RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2024

Viabahn endoprosthesis for femoropopliteal aneurysm repair: safety, success rates, and long-term patency.

CVIR endovascular

RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2023

FORWARD Study of GORE VIABAHN Balloon-Expandable Endoprostheses and Bare Metal Stents in the United States, European Union, United Kingdom, Australia, and New Zealand When Placed to Treat Complex Iliac Occlusive Disease: Protocol for a Randomized Superiority Trial.

JMIR research protocols

RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2023

Use of real-world data and clinical registries to identify new uses of existing vascular endografts: combined use of GORE EXCLUDER Iliac Branch Endoprosthesis and GORE VIABAHN VBX Balloon Expandable Endoprosthesis.

BMJ surgery, interventions, & health technologies

RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2022

Outcomes of Gore iliac branch endoprosthesis with internal iliac component versus Gore Viabahn VBX.

Journal of vascular surgery

RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2022

Twelve-Month Outcomes From the Japanese Post-Market Surveillance Study of the Viabahn Endoprosthesis as Treatment for Symptomatic Peripheral Arterial Disease in the Superficial Femoral Arteries.

Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists

RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2022

Individual patient data meta-analysis of patients treated with a heparin-bonded Viabahn in the femoropopliteal artery for chronic limb-threatening ischemia.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions

RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2021

Outcomes of chimney and fenestrated endografting using Viabahn VBX and atrium iCAST stents.

The Journal of cardiovascular surgery

RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2021

Performance of the Gore VBX Balloon Expandable Endoprosthesis as Bridging Stent-Graft in Branched Endovascular Aortic Repair for Thoracoabdominal Aneurysms.

Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists

RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2021

Bail-out technique to detach a locked Viabahn endoprosthesis in branched thoracic endovascular aortic repair.

Journal of vascular surgery cases and innovative techniques

RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2020

First/Preliminary Experience of Gore Viabahn Balloon-Expandable Endoprosthesis as Bridging Stent in Fenestrated and Branched Endovascular Aortic Repair.

Annals of vascular surgery

RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2015

Surgeon custom-made iliac branch device to salvage hypogastric artery during endovascular aneurysm repair.

Journal of Korean medical science

RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2014

Transaortic modification of the Viabahn open revascularization technique (VORTEC) to facilitate renal artery revascularization in a hybrid EVAR procedure.

Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists

RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2012

ViPS (Viabahn Padova Sutureless) technique: preliminary results in the treatment of peripheral arterial disease.

Annals of vascular surgery

Other View Source →
PubMed • 2012

New surgical and hybrid techniques for crural and pedal anastomoses.

The Journal of cardiovascular surgery

RCT|prospective|retrospective|case Series|other View Source →

Frequently Asked Questions

What are the clinical indications for GORE VIABAHN Endoprosthesis?

The device is indicated for the treatment of peripheral artery disease, particularly in cases of in-stent restenosis and complex femoropopliteal lesions.

What outcomes have been reported in clinical studies?

Studies report primary patency rates of 62.4% and secondary patency rates of 82.3% over five years, with significant symptom improvement.

What complications have been reported?

Reported complications include a 19.9% rate of device-related serious adverse events, with no stent fractures observed.

Disclaimer: This page compiles publicly available regulatory and published clinical evidence for educational reference. It does not constitute medical advice, product endorsement, or a recommendation for clinical use. Always consult manufacturer documentation and clinical judgment for patient care decisions.

📬 Stay Updated

Get the latest vascular education content delivered to your inbox.